Last SFr.259.40 CHF
Change Today +3.30 / 1.29%
Volume 180.6K
As of 3:25 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (ROG) Snapshot

Open
SFr.257.10
Previous Close
SFr.260.20
Day High
SFr.259.50
Day Low
SFr.257.00
52 Week High
12/3/14 - SFr.295.80
52 Week Low
01/22/15 - SFr.238.80
Market Cap
223.4B
Average Volume 10 Days
1.9M
EPS TTM
SFr.10.99
Shares Outstanding
702.6M
EX-Date
03/5/15
P/E TM
23.6x
Dividend
SFr.8.00
Dividend Yield
3.12%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (ROG)

roche holding ag-genusschein (ROG) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Europe, North America, and Asia. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. The company also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; pharmacogenomics; physical fitness and platelet function testing; PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. In addition, it offers products for researchers, such as amplification, cell analysis, gene expression, gene knockdown, genome sequencing, microarrays, nucleic acid purification, protein analysis, PCR systems, and transfection products. The company has collaboration agreements with AmorChem, AbbVie, Xenon Pharmaceuticals, Stratos Genomics, The Garvan Institute, Cornell University, and University of Washington. The company was founded in 1896 and is headquartered in Basel, Switzerland.

88,509 Employees
Last Reported Date: 01/28/15
Founded in 1896

roche holding ag-genusschein (ROG) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.3M
Chief Financial Officer and IT Officer
Total Annual Compensation: SFr.4.1M
Chief Operating Officer of Pharmaceuticals di...
Total Annual Compensation: SFr.5.0M
Chief Operating Officer of Diagnostics Divisi...
Total Annual Compensation: SFr.2.5M
General Counsel and Corporate Secretary
Total Annual Compensation: SFr.2.8M
Compensation as of Fiscal Year 2014.

roche holding ag-genusschein (ROG) Key Developments

Roche Holding AG Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM

Roche Holding AG Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Juan Carlos Lopez, Head of Academic Relations & Collaborations.

Roche Holding AG Licenses Additional EGFR Pathway-Related Intellectual Property to QIAGEN

Roche announced that the company has entered into an agreement with QIAGEN that includes a provision of non-exclusive licenses to recently granted Roche patents pertaining to the detection of mutations in the EGFR pathway (including in the KRAS gene). The licenses apply to testing products which detect these mutations using molecular techniques including PCR, next generation sequencing (NGS) and other applications to aid in identification of cancer patients eligible for treatment with certain tyrosine kinase inhibitors. The licenses can be applied to existing and future products.

Roche Holding AG Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015

Roche Holding AG Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Presentation Date & Speakers: Mar-03-2015, Alexander Breidenbach, Director, Global Business Development, Stephen Sands, Commercial Lead, Oncology/Immunology. Mar-04-2015, Jason Coloma, Global Head Venture & Innovation at Roche Partnering.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROG:VX SFr.259.20 CHF +3.10

ROG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €133.30 EUR -0.062
Gilead Sciences Inc $103.42 USD +0.355
Merck & Co Inc $57.98 USD +0.10
Pfizer Inc $34.47 USD -0.17
Sanofi €87.84 EUR 0.00
View Industry Companies
 

Industry Analysis

ROG

Industry Average

Valuation ROG Industry Range
Price/Earnings 24.8x
Price/Sales 4.6x
Price/Book 11.7x
Price/Cash Flow 20.2x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.